Yahoo Finance

REGULATED INFORMATION

A company with a powerful proprietary Nanobody platform and a hybrid business model
which together have generated multiple later-stage clinical assets and a wide range of
promising discovery programmes

GHENT, Belgium, 26 February 2015 - Ablynx [Euronext Brussels: ABLX] today announced its consolidated results for 2014, which have been prepared in accordance with IFRS as adopted by the European Union.

The FY14 results will be discussed during a webcast presentation today at 3 pm CET, 9 am EST
The webcast may be accessed on the home page of the Ablynx website at www.ablynx.com or by
clicking here. To participate in the Q&A, please dial +32(0)2 404 06 62
with confirmation code 9002858

Operating highlights

• Achieved positive results from six clinical studies, including clinical proof-of-concept Phase II data for its anti-vWF Nanobody, caplacizumab, in patients with acquired TTP

• Announced the initiation of four clinical studies, two wholly-owned and two partnered programmes (Merck Serono and AbbVie)

• In February, further validated the discovery platform through a major discovery and licensing agreement with Merck & Co. in the field of immuno-oncology (with a focus on multi-specific Nanobodies) with an upfront payment of €20 million, €10.7 million in research funding and up to €1.7 billion in potential milestone payments and royalties. Made encouraging progress with a number of programmes since the start of this collaboration

• In June, presented positive pre-clinical proof-of-concept data for Nanobodies targeting the potassium voltage-gated ion channel, Kv1.3, in a rat model

• In September, signed a second licensing deal with the Chinese biopharmaceutical company, Eddingpharm, this time for the development and commercialisation of the anti-TNFa Nanobody, ozoralizumab, in Greater China in all indications, including RA

• In November, presented strong in vivo proof-of-concept data for its inhaled anti-RSV Nanobody, ALX-0171, in a neonatal lamb model of RSV infection in infants

• In November, strengthened the management team with the appointment of Johan Heylen from GSK as Chief Commercial Officer

Financial highlights

• Cash received from collaborations of €30.1 million (2013: €157.6 million)

• Growth in total income of 37% to €49.3 million (2013: €35.9 million)

• Net loss for the period reduced by 35% to €12.7 million (2013: €19.5 million)

• Net cash burn of €34.1 million, excluding the net proceeds from the private placement of new shares

• In July, raised €41.7 million in a private placement of new shares (accelerated book building procedure)

• At 31^st December 2014, strong financial position of €206.2 million in cash, cash equivalents, restricted cash and short-term investments (2013: €200.4 million)